Custom antibody production services
from €310

Bangor University, UK

Dr. David Pryce, Lecturer in Biomedical Sciences (Immunology)

“I requested ProteoGenix’s services for the generation of an anti-peptide monoclonal antibody to be used in my research. I required the antibody primarily for western blotting and immunoprecipitation experiments. Although the peptide antigen proved challenging in terms of immunogenicity, ProteoGenix was able to propose a range of customised strategies to overcome production issues encountered and finally succeeded in generating not only one but three antibodies of interest, thus offering me extra options in terms of final choice and use. During the whole project, Proteogenix strived to ensure maximal quality and to adapt to my needs, and my Account Manager always provided prompt and helpful services and solutions. I can highly commend both the level of expertise and the service I received.”

Lund University, Sweden

Dr. Anna Blom, Professor

“I highly recommend ProteoGenix for their fast and efficient services, providing top-quality antibodies suitable for diverse applications. Their exceptional communication, quick turnaround time, and reasonable pricing make them an excellent choice even for non-standard projects.”

The University of Tokyo, Japan

Naoya Uchida, M.D., Ph.D.

“We requested ProteoGenix’s services for the development of antibodies against a specific surface protein by phage display. Their naive human library was built from 368 donors for maximized diversity. This unique quality and their reactivity convinced us to work with them. They successfully identified various candidates that all bound well and specifically to our antigen. I appreciated their expertise for the high quality of their services as well as their good responses to my questions for this project.”

Trident Biopharm Solutions, London, UK

Khelan Patel, Managing Director

“I requested ProteoGenix’s services for the generation of neutralizing anti-COVID-19 antibodies by Phage Display. They designed an optimised strategy for this purpose which led to great results, with 4 antibodies identified as cross-reactive and neutralizing against all the current variants of concerns. During the whole project, Proteogenix strived to ensure the best quality of their final deliverables, especially by including additional screenings against emerging variants as the pandemic evolved. Their proactivity was key to obtaining promising and relevant blocking antibodies in only a few months. I highly recommend them for both their level of expertise and the personalised service they offer.”

Nanyang Technological University, Singapore

Dr. Abbas El Sahili, Senior Research Fellow

“We are developing a novel immunotherapy and needed a highly potent monoclonal antibody. Currently the development of a novel antibody requires lengthy and expensive humanization process. We thus decided to screen for binders a human antibody library via phage display screening instead of humanizing a murine antibody. Proteogenix proposed just that. We provided our purified target antigen and in only one month several high affinity binders were obtained. We were able to quickly clone and produce a monoclonal antibody from the sequences provided. What should have taken 6 to 8 months was done in 2 for a fraction of the cost and for an equivalent quality.”